ECTRIMS Symposium Highlights
Advancing MS care: New treatments and technologies
What can we do to further customise care for people with MS now and in the future? In this virtual satellite symposium moderated by Thomas Berger, Joep Killestein and Jiwon Oh navigate:
The latest possibilities for tailored approaches to treatment
What the future may bring for personalised MS care by updating us on digital innovations for disease monitoring
Insights and examples of how advances in artificial intelligence could enhance clinical care
What treatments and strategies are becoming available
to improve the individual patient experience with customised MS care?
to improve the individual patient experience with customised MS care?
What established therapies have been modified to give clinicians the possibility to better customise their care for people with MS? How can extended interval dosing with a monoclonal antibody targeting VLA-4 support a more personalised approach to treatment? Professor Joep Killestein discusses initial results from clinical trials investigating the relevant outcomes observed with next generation MS therapies. He also dives into new considerations in MS treatment decision making, starting with the latest insights around every 6-week dosing with anti-VLA4 therapy, followed by discussing the relevance of MS patient immune function in the COVID era.
Thomas Berger MD, MSc (Chair)
Medical University of Vienna
Vienna, Austria
Joep Killestein MD, PhD
Amsterdam University Medical Center
Amsterdam, Netherlands
What digital tools are currently in development to better monitor and support patients in MS care?
How can digital tools help clinicians better understand how each of their patients are doing between visits and hence assess whether their disease is adequately controlled? Are there some examples of promising digital applications? Professor Killestein describes initial results with three applications: Konectom (a research tool), Neurokeys and MS Sherpa (both apps available in certain countries), that are currently being assessed for their applicability in measuring important outcomes in people with MS and providing validated, interpretable data.
Thomas Berger MD, MSc (Chair)
Medical University of Vienna
Vienna, Austria
Joep Killestein MD, PhD
Amsterdam University Medical Center
Amsterdam, Netherlands
Can artificial intelligence (AI) enhance clinical care for people with multiple sclerosis (MS)?
Can artificial intelligence (AI) shape the future of personalised MS care? Where does the latest technology of deep learning have the greatest clinical utility? Associate Professor Jiwon Oh discusses how AI can be used to help healthcare professionals in their everyday practice and explores ways that deep learning could predict disease activity, treatment outcomes and help to personalise disease prognosis.
Thomas Berger MD, MSc (Chair)
Medical University of Vienna
Vienna, Austria
Jiwon Oh MD, PhD
Keenan Research Centre of the
Li Ka Shing Knowledge Institute
Toronto, Canada
Biogen-130852.
Date of preparation: October 2021.